Diverse ERBB2/ERBB3 activating alterations and coalterations have implications for HER2/3-targeted therapies across solid tumors Journal Article
| Authors: | Liu, D.; Jee, J.; Drilon, A.; Heilmann, A. M.; Allen, J. M.; Schrock, A. B.; Keller-Evans, R. B.; Li, B. T. |
| Article Title: | Diverse ERBB2/ERBB3 activating alterations and coalterations have implications for HER2/3-targeted therapies across solid tumors |
| Abstract: | SIGNIFICANCE: CGP provides genomic context for HER2 status beyond the information provided by IHC and FISH, including detection of ERBB2 mutations and co-alterations that may suggest sensitivity/resistance to HER2-directed therapies, and is therefore crucial for guiding treatment choice and understanding individual patient response. ©2025 The Authors; Published by the American Association for Cancer Research. |
| Keywords: | genetics; mutation; neoplasm; neoplasms; metabolism; epidermal growth factor receptor 2; drug resistance; drug resistance, neoplasm; receptor, erbb-2; drug therapy; epidermal growth factor receptor 3; molecularly targeted therapy; erbb2 protein, human; molecular targeted therapy; receptor, erbb-3; humans; human; erbb3 protein, human |
| Journal Title: | Cancer Research Communications |
| Volume: | 5 |
| Issue: | 4 |
| ISSN: | 2767-9764 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2025-04-01 |
| Start Page: | 680 |
| End Page: | 693 |
| Language: | English |
| DOI: | 10.1158/2767-9764.Crc-24-0620 |
| PUBMED: | 40178042 |
| PROVIDER: | scopus |
| PMCID: | PMC12022956 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work